Document Detail


Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.
MedLine Citation:
PMID:  23036075     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Inflammatory bowel disease (IBD) is a chronic relapsing idiopathic disease. In clinical terms, most patients require lifelong medication associated with possible unpleasant adverse effects. Oral colon-specific drug delivery systems are designed to deliver therapeutic drugs to the inflamed colon to target pathophysiological manifestations of IBD. The aim is to maintain the drug with proper concentration in the inflamed colon, to enhance drug residence time and to minimize drug absorption by healthy tissues.
AREAS COVERED: This review addresses the main barriers for colon-specific drug delivery from organism, tissue and cell levels, respectively. It also summarizes novel colon-specific therapeutic strategies using microparticles and nanoparticles.
EXPERT OPINION: Oral colon-specific drug delivery represents a possible approach toward efficient treatment of IBD. As the environment of the gastrointestinal tract is harsh and intricate, this approach requires that drug carriers can respond to specific environmental factors of the inflamed colon, permitting stimulus-responsive release of loaded drugs to specific cells or even into specific organelles within cells.
Authors:
Bo Xiao; Didier Merlin
Related Documents :
25100635 - Zwitterionic nanoparticles constructed with well-defined reduction-responsive shell and...
7957505 - H2-receptor antagonists are scavengers of oxygen radicals.
2517505 - Effects of sodium valproate and oxygen on the craniofacial skeletal pattern in the cd-1...
16638925 - Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-se...
24180495 - Overcoming resistance to targeted anticancer drugs.
6119725 - Enhancement of the avoidance-suppressing effects of neuroleptic agents after repeated a...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2012-10-05
Journal Detail:
Title:  Expert opinion on drug delivery     Volume:  9     ISSN:  1744-7593     ISO Abbreviation:  Expert Opin Drug Deliv     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-22     Completed Date:  2013-04-26     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228421     Medline TA:  Expert Opin Drug Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  1393-407     Citation Subset:  IM    
Affiliation:
Center for Diagnostics and Therapeutics, Department of Biology, Georgia State University, Atlanta, 30302, USA. bxiao@gsu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Colon / drug effects*
Drug Carriers
Drug Delivery Systems*
Humans
Inflammatory Bowel Diseases / drug therapy*
Nanoparticles / administration & dosage
Pharmaceutical Preparations / administration & dosage
Grant Support
ID/Acronym/Agency:
R01-DK-071594/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Drug Carriers; 0/Pharmaceutical Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The feasibility of rapid baseline objective physical activity measurement in a natural experimental ...
Next Document:  Cross-Cultural Adaptation and Validation of the Brazilian Portuguese Version of the Pain Catastrophi...